

LAW OFFICES

KILYK & BOWERSOX, P.L.L.C.

Intellectual Property Law

LUKE A. KILYK* (PA, DC)
LEONARD D. BOWERSOX
ARASH BEHRAVESH* (MA)
JASBIR SINGH
MATTHEW T. GILL

Of Counsel:
WILLIAM CHARLES JAMISON
SAMUEL P. BURKHOLDER* (PA, DC, NJ)

53 A East Lee Street
WARRENTON, VA 20186

TEL.: (540) 428-1701
FAC.: (540) 428-1720
(540) 428-1721

FAIRFAX OFFICE
3603-E Chain Bridge Road
Fairfax, Virginia 22030

Email: lkilyk@kbpatentlaw.com
Website: <http://www.kbpatentlaw.com>

*Admitted only in states indicated


PLEASE DIRECT CORRESPONDENCE TO OUR WARRENTON OFFICE

FACSIMILE TRANSMISSION COVER SHEET

DATE: April 1, 2004

TO: Office of Initial Patent Examination's
Filing Receipt Corrections
Group Art Unit 1614
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RE: U.S. Patent Application No. 10/723,208
For: NOVEL ARYLAMINOPROPANE ANALOGUES AND THEIR USE FOR THE
TREATMENT OF GLAUCOMA
Our Ref: 2162 (3010-009-01)

FROM: Luke A. Kilyk, Esq. 

FAC. TEL. NO.: 1-703-746-9195

NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 7

Items Attached: Second Request for Corrected Filing Receipt -- 2 pages
Marked-up Certificate of Correction Showing Changes -- 2 pages
Copy of Declaration -- 2 pages

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-746-9195 on April 1, 2004.


Donald S. Prater
Name


Signature

THE INFORMATION CONTAINED IN THIS MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. This message may also be an attorney/client communication which is privileged and confidential. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by calling us collect and return the original message to us at the above address by mail. Thank you.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-746-9195 on April 1, 2004.

Donald S. Prater
Name (Print)


Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HELLBERG et al.)	Examiner: Unassigned
)	
Application No.: 10/723,208)	Group Art Unit: 1614
)	
Filed: November 26, 2003)	Confirmation No.: 8524
)	
Docket No.: 2162 (3010-009-01))	Customer No.: 33432

For: NOVEL ARYLAMINOPROPANE ANALOGUES AND THEIR USE FOR THE TREATMENT OF
GLAUCOMA

SECOND REQUEST FOR CORRECTED FILING RECEIPT

Office of Initial Patent Examination's
Filing Receipt Corrections
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 1, 2004

Sir:

The applicants received a Response to Request for Corrected Filing Receipt dated March 23, 2004. In this response from the United States Patent and Trademark Office, the PTO has indicated that the application to which priority is claimed was filed over a year prior to the filing date of the present application and therefore the referenced application cannot be claimed as domestic or foreign priority. However, the position taken by the U.S. Patent and Trademark Office is incorrect. It is respectfully noted, and as previously indicated, that the present application is first, a continuation of International Patent Application No. PCT/US02/16842 filed May 30, 2002. This International Patent Application (which designated the United States) claims the benefit of United States Provisional Patent Application No. 60/295,426 filed June 1, 2001. Accordingly, the benefit of the provisional application was claimed within a year of the filing date of the provisional application by way of the International Patent Application. A chain of continuity clearly exists

Second Request For Corrected Filing Receipt
U.S. Patent Application No.: 10/723,208

between the present application and the provisional application by way of the International Patent Application. This is further shown in the copy of the Declaration which was previously submitted and is again attached. Accordingly, the PTO's position is incorrect and needs to be corrected. Applicants again request a corrected filing receipt.


Therefore, please supply the undersigned attorney with a corrected filing receipt for the above-identified application. The undersigned also respectfully requests that the Patent and Trademark Office records be amended to reflect the corrections.

Therefore, it is respectfully submitted that a Corrected Filing Receipt should be issued as follows:

The domestic priority data as claimed by applicant should read: This application is a CON of PCT/US02/16842 filed May 30, 2002 which in turn claims the benefit of U.S. Provisional Application No. 60/295,426, filed June 1, 2001, as set forth in the Declaration (copy enclosed). A copy of the Filing Receipt reflecting this correction is attached. Please supply the undersigned attorney with a corrected filing receipt for the above-identified application.

It is believed no fee is required with this filing. However, in the event fees are required in connection with this paper, please charge our Deposit Account No. 50-0925.

Respectfully submitted,



Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No. 2162 (3010-009-01)
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel: (540) 428-1701
Fax: (540) 428-1720



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/723,208	11/26/2003	1614	770	2162 (3010-009-1)		8	1

33432
KILYK & BOWERSOX, P.L.L.C.
53 A EAST LEE STREET
WARRENTON, VA 20186

RECEIVED
FEB 27 2004

KILYK & BOWERSOX, P.L.L.C.

CONFIRMATION NO. 8524

FILING RECEIPT



OC000000011979147

Date Mailed: 02/26/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Mark R. Hellberg, Arlington, TX;
Abdelmoula Namil, Arlington, TX;

Domestic Priority data as claimed by applicant

This application is a CON of PCT/US02/16842 05/30/2002

Foreign Applications

→ U.S. Provisional Application No. 60/295,426 filed June 1, 2001

If Required, Foreign Filing License Granted: 02/25/2004

Projected Publication Date: 06/03/2004

Non-Publication Request: No

Early Publication Request: No

DOCKETED

DUE DATE 3010-009-01

DKT NO 3010-009-01

BY Kelley

Title

Novel arylaminopropane analogues and their use for the treatment of glaucoma

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).